Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1368 ARTÍCULOS , VIENDO DEL 1201 AL 1215

Aggressive Behaviors in Alzheimer Disease and Mild Cognitive Impairment: Systematic Review and Meta-Analysis

Yu R, Topiwala A, Jacoby R, Fazel S.

Am J Geriatr Psychiatry. 2019 Mar;27(3):290-300. doi: 10.1016/j.jagp.2018.10.008. Epub 2018 Oct 19.

Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome

Rafii MS.

Dev Neurobiol. 2019 Jul;79(7):711-715. doi: 10.1002/dneu.22658. Epub 2018 Dec 16.

Diabetes and Alzheimer's Disease: A Link not as Simple as it Seems

Salas IH, De Strooper B.

Neurochem Res. 2019 Jun;44(6):1271-1278. doi: 10.1007/s11064-018-2690-9. Epub 2018 Dec 6.

Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data

Sörensen A, Blazhenets G, Rücker G, Schiller F, Meyer PT, Frings L; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2019;21:101637. doi: 10.1016/j.nicl.2018.101637. Epub 2018 Dec 10.

Olfactory function in mild cognitive impairment and Alzheimer's disease: A meta-analysis

Jung HJ, Shin IS, Lee JE.

Laryngoscope. 2019 Feb;129(2):362-369. doi: 10.1002/lary.27399. Epub 2018 Nov 22.

A survey on applications and analysis methods of functional magnetic resonance imaging for Alzheimer's disease

Forouzannezhad P, Abbaspour A, Fang C, Cabrerizo M, Loewenstein D, Duara R, Adjouadi M.

J Neurosci Methods. 2019 Apr 1;317:121-140. doi: 10.1016/j.jneumeth.2018.12.012. Epub 2018 Dec 26.

Seizure in Alzheimer's Disease: An Underestimated Phenomenon

Asadollahi M, Atazadeh M, Noroozian M.

Am J Alzheimers Dis Other Demen. 2019 Mar;34(2):81-88. doi: 10.1177/1533317518813551. Epub 2018 Dec 30.

Phosphoproteomics of Alzheimer disease brain: Insights into altered brain protein regulation of critical neuronal functions and their contributions to subsequent cognitive loss

Butterfield DA.

Biochim Biophys Acta Mol Basis Dis. 2019 Aug 1;1865(8):2031-2039. doi: 10.1016/j.bbadis.2018.08.035. Epub 2018 Aug 29.

Long-Lasting Neuropsychological Effects of a Computerized Cognitive Training in Patients Affected by Early Stage Alzheimer's Disease: Are They Stable Over Time?

Cavallo M, Angilletta C.

J Appl Gerontol. 2019 Jul;38(7):1035-1044. doi: 10.1177/0733464817750276. Epub 2018 Jan 2.

Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials

Tsoi KK, Chan JY, Chan FC, Hirai HW, Kwok TC, Wong SY.

Clin Pharmacol Ther. 2019 Jan;105(1):121-130. doi: 10.1002/cpt.1104. Epub 2018 Jun 19.

Drug development for Alzheimer's disease: review

Lao K, Ji N, Zhang X, Qiao W, Tang Z, Gou X.

J Drug Target. 2019 Feb;27(2):164-173. doi: 10.1080/1061186X.2018.1474361. Epub 2018 Jun 20.

An expanded theory of Alzheimer's caregiving

Lang SF, Fowers BJ.

Am Psychol. 2019 Feb-Mar;74(2):194-206. doi: 10.1037/amp0000323. Epub 2018 May 24.

Neuro-nutrients as anti-alzheimer's disease agents: A critical review

Ravi SK, Narasingappa RB, Vincent B.

Crit Rev Food Sci Nutr. 2019;59(18):2999-3018. doi: 10.1080/10408398.2018.1481012. Epub 2018 Jun 21.

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease

Lu M, Brashear HR.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):326-335. doi: 10.1002/cpdd.584. Epub 2018 Jun 19.

Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies

Lon HK, Mendonca N, Goss S, Othman AA, Locke C, Jin Z, Rendenbach-Mueller B.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):290-303. doi: 10.1002/cpdd.598. Epub 2018 Jul 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias